Abstract:Objective: Pulmonary Arterial Hypertension (PAH) is a fatal disease with high mortality rates and late diagnosis, currently lacking complete cure. Metabolic abnormalities play a crucial role in the pathophysiological process of pulmonary vascular remodeling. This study aimed to identify metabolic-related genes that may play important roles in PAH and analyze their expression and function and the clinical significance. Methods: Transcriptomic data were retrieved from the GEO database, including tissue transcriptome data (GSE113439, GSE53408, GSE198618) and single-cell transcriptome data (GSE210248, GSE203274); "limma" and "DEseq2" packages were used to identify differentially expressed genes (DEGs); By WGCNA and Boruta algorithm, we identified feature genes related to PAH; Transcription factor network analysis was analyzed using the "RTN" package; Single-cell and single-nucleus transcriptome data were analyzed using the Seurat pipeline; Concentration of key genes’ protein level in PAH were evaluated using ELISA. Results: The study found increased glycolysis, disrupted carnitine shuttle pathway, enhanced fatty acid degradation, decreased oxidative phosphorylation, and augmented polyamine synthesis in PAH. PIGN, SLC25A24, RPL5, PIK3CA, PIK3CB, DNM1L, SETD2, TPH1, ITPR2, PRKAA1, PTPN11, and PDK4 were identified as metabolic-related genes associated with PAH. PDK4 was significantly increased in pulmonary artery endothelial cells (PAECs) and right ventricular tissues of decompensated right heart failure, mainly expressed in cardiomyocytes. PDK4 was significantly elevated in the PAH group (control group: 4.15 ± 0.53 ng/ml; idiopathic pulmonary arterial hypertension group: 5.28 ± 0.77 ng/ml, p-value <0.001), and showed linear correlations with mean pulmonary artery pressure (r=0.51, p=0.00033) and pulmonary vascular resistance (r=0.44, p=0.0019). Conclusion: This study provides important insights into the role of metabolic reprogramming and mitochondrial dysfunction in the pathogenesis of PAH, identifies 12 potential pathogenic regulatory factors related to metabolism, and suggests that PDK4 is strongly correlated with hemodynamic parameters of the disease, potentially participating in PAH and cardiac remodeling under right heart overload.

Abstract 12562: DYRK1A/PPARG/EGR1 Pathway Elicits Endothelial Dysfunctions and Predispose to Developing Pulmonary Hypertension in Down Syndrome

Isogenic Pairs of Induced-Pluripotent Stem-Derived Endothelial Cells Identify DYRK1A/PPARG/EGR1 Pathway is Responsible for Down Syndrome-Associated Pulmonary Hypertension.

Ddx5 Targeted Epigenetic Modification of Pericytes in Pulmonary Hypertension after Intrauterine Growth Restriction

Increased Lung Expression of Anti-Angiogenic Factors in Down Syndrome: Potential Role in Abnormal Lung Vascular Growth and the Risk for Pulmonary Hypertension

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome

Abstract 14257: Endothelial SOX17 Deficiency Induces Pulmonary Arterial Hypertension

Abstract 17370: Activation of Endothelial GCN2 Kinase Contributes to Pulmonary Vascular Remodeling and Pulmonary Arterial Hypertension

Multimodal analysis of dysregulated heme metabolism, hypoxic signaling, and stress erythropoiesis in Down syndrome

RUNX1 Upregulation Causes Mitochondrial Dysfunction Via Regulating the PI3K-Akt Pathway in Ipsc from Patients with Down Syndrome

DSCAM/PAK1 pathway suppression reverses neurogenesis deficits in iPSC-derived cerebral organoids from patients with Down syndrome

Abstract 4141118: Identifying PDK4 As A Metabolic Regulator in Pulmonary Arterial Hypertension: Insights from Bulk, Single-cell Transcriptomics Analysis and Clinical Validation

Endothelial Dec1-PPARγ Axis Impairs Proliferation and Apoptosis Homeostasis under Hypoxia in Pulmonary Arterial Hypertension.

Updated review on pulmonary arterial hypertension: Differences between down syndrome and non-down syndrome populations

Realizing the Potential of Exploiting Human IPSCs and Their Derivatives in Research of Down Syndrome

Upregulation of Endothelial DKK1 (Dickkopf 1) Promotes the Development of Pulmonary Hypertension Through the Sp1 (Specificity Protein 1)/SHMT2 (Serine Hydroxymethyltransferase 2) Pathway

Ddx5 Targeted Epigenetic Modification of Pericytes in Pulmonary Hypertension Following Intrauterine Growth Restriction

Interferon hyperactivity impairs cardiogenesis in Down syndrome via downregulation of canonical Wnt signaling

Abstract 15967: Unravelling the Role of Deoxyhypusine Synthase-Mediated Hypusination of eIF5A in Pulmonary Arterial Hypertension

Abnormal mitochondria in Down syndrome iPSC-derived GABAergic interneurons and organoids

Mural Cell SDF1 Signaling Is Associated with the Pathogenesis of Pulmonary Arterial Hypertension